SEE LATEST
SPONSORED LEGISLATION
HB277 - Consumer protection; transparency in ticket fees, civil penalties.
Dan I. Helmer, Alfonso H. Lopez, Laura Jane Cohen
Last updated 9 months ago
5 Co-Sponsors
Consumer protection; transparency in ticket fees; civil penalties. Requires any person selling or reselling a ticket to an event to clearly and conspicuously display the total cost of the ticket from the first time a price is displayed and any time thereafter. The bill allows for a civil penalty of not less than $1,000 nor more than $5,000 for each violation.
STATUS
Failed
HB335 - Tipped employees; DOLI to study increasing wages and address wage theft by employers.
Debra D. Gardner, Dan I. Helmer, Bonita Grace Anthony
Last updated 8 months ago
10 Co-Sponsors
Department of Labor and Industry; tipped employee wages; work group. Directs the Department of Labor and Industry to convene a work group to study (i) options for increasing tipped employee minimum cash wages, (ii) circumstances related to wage theft or payment inequities by employers of tipped wage employees, and (iii) amending the penalty provisions related to employee remedies and employer penalties for violations of minimum wage requirements. The bill directs the work group to submit a report of its findings no later than December 1, 2024. Department of Labor and Industry; tipped employee wages; work group. Directs the Department of Labor and Industry to convene a work group to study (i) options for increasing tipped employee minimum cash wages, (ii) circumstances related to wage theft or payment inequities by employers of tipped wage employees, and (iii) amending the penalty provisions related to employee remedies and employer penalties for violations of minimum wage requirements. The bill directs the work group to submit a report of its findings no later than December 1, 2024.
STATUS
Vetoed
HB373 - Financial institutions; reporting financial exploitation of elderly or vulnerable adults.
Michael B. Feggans, Richard C. Sullivan, Dan I. Helmer
Last updated 11 months ago
3 Co-Sponsors
Financial institutions; reporting financial exploitation of elderly or vulnerable adults. Permits a financial institution, as defined in the bill, to allow an elderly or vulnerable adult, as defined in the bill, to submit and periodically update a list of trusted persons whom such financial institution or financial institution staff, as defined in the bill, may contact in the case of suspected financial exploitation of such adult. In such a case, the bill also allows a financial institution or financial institution staff to convey such suspicion to one or more certain individuals, provided that the recipient of such conveyance is not the suspected perpetrator of financial exploitation. The bill provides that a financial institution or financial institution staff shall be immune from any criminal, civil, or administrative liability for any act taken or omission made in accordance with the bill's provisions.
STATUS
Introduced
HB570 - Prescription Drug Affordability Board; established, drug cost affordability review, report.
Karrie K. Delaney, Nadarius E. Clark, Dan I. Helmer
Last updated 8 months ago
27 Co-Sponsors
Prescription Drug Affordability Board established; drug cost affordability review. Establishes the Prescription Drug Affordability Board for the purpose of protecting the citizens of the Commonwealth and other stakeholders within the health care system from the high costs of prescription drug products. The bill requires the Board to meet in open session at least four times annually, with certain exceptions and requirements enumerated in the bill. Members of the Board are required to disclose any conflicts of interest, as described in the bill. The bill also creates a stakeholder council for the purpose of assisting the Board in making decisions related to drug cost affordability. The bill tasks the Board with identifying prescription, generic, and other drugs, as defined in the bill, that are offered for sale in the Commonwealth and, at the Board's discretion, conducting an affordability review of any prescription drug product. The bill lists factors for the Board to consider that indicate an affordability challenge for the health care system in the Commonwealth or high out-of-pocket costs for patients. The bill also provides that any person aggrieved by a decision of the Board may request an appeal of the Board's decision and that the Attorney General has authority to enforce the provisions of the bill. The bill provides that the Board shall establish no more than 12 upper payment limit amounts annually between January 1, 2025, and January 1, 2028. Prescription Drug Affordability Board established; drug cost affordability review. Establishes the Prescription Drug Affordability Board for the purpose of protecting the citizens of the Commonwealth and other stakeholders within the health care system from the high costs of prescription drug products. The bill requires the Board to meet in open session at least four times annually, with certain exceptions and requirements enumerated in the bill. Members of the Board are required to disclose any conflicts of interest, as described in the bill. The bill also creates a stakeholder council for the purpose of assisting the Board in making decisions related to drug cost affordability. The bill tasks the Board with identifying prescription, generic, and other drugs, as defined in the bill, that are offered for sale in the Commonwealth and, at the Board's discretion, conducting an affordability review of any prescription drug product. The bill lists factors for the Board to consider that indicate an affordability challenge for the health care system in the Commonwealth or high out-of-pocket costs for patients. The bill also provides that any person aggrieved by a decision of the Board may request an appeal of the Board's decision and that the Attorney General has authority to enforce the provisions of the bill. The bill provides that the Board shall establish no more than 12 upper payment limit amounts annually between January 1, 2025, and January 1, 2028. The bill requires the Board to report its findings and recommendations to the General Assembly twice annually, beginning on July 1, 2025, and December 31, 2025. Provisions of the bill shall apply to state-sponsored and state-regulated health plans and health programs and obligate such policies to limit drug payment amounts and reimbursements to an upper payment limit amount set by the Board, if applicable, following an affordability review. The bill specifies that Medicare Part D plans shall not be bound by such decisions of the Board. The bill also requires the nonprofit organization contracted by the Department of Health to provide prescription drug price transparency to provide the Board access to certain data reported by manufacturers. The bill has a delayed effective date of January 1, 2025, and is identical to
STATUS
Vetoed
HB319 - Firearms instructors & safety prog.; removes reference to NRA & U.S. Concealed Carry Assoc. in Code.
Dan I. Helmer
Last updated 11 months ago
1 Co-Sponsor
Firearms instructors and safety programs; National Rifle Association and United States Concealed Carry Association. Removes references to the National Rifle Association (the NRA) and the United States Concealed Carry Association from the Code that allow the organizations to certify ranges and instructors and for courses offered by them to serve as proof of demonstrated competence in firearms safety and training for the purpose of obtaining a concealed handgun permit or receiving training as a minor in the use of pneumatic guns. The bill also repeals authority for special license plates in support of the NRA.
STATUS
Introduced
HB348 - Employment; paid sick leave, civil penalties.
Jeion A. Ward, Dan I. Helmer, Alfonso H. Lopez
Last updated 11 months ago
4 Co-Sponsors
Employment; paid sick leave; civil penalties. Expands Employment; paid sick leave; civil penalties. Expands provisions of the Code that currently require one hour of paid sick leave for every 30 hours worked for home health workers to cover all employees of private employers and state and local governments. The bill requires that employees who are employed and compensated on a fee-for-service basis accrue paid sick leave in accordance with regulations adopted by the Commissioner of Labor and Industry. The bill provides that employees transferred to a separate division or location remain entitled to previously accrued paid sick leave and that employees retain their accrued sick leave under any successor employer. The bill allows employers to provide a more generous paid sick leave policy than prescribed by its provisions. Employees, in addition to using paid sick leave for their physical or mental illness or to care for a family member, may use paid sick leave for their need for services or relocation due to domestic abuse, sexual assault, or stalking. The bill provides that certain health care workers who work no more than 30 hours per month may waive the right to accrue and use paid sick leave. The bill also provides that employers are not required to provide paid sick leave to certain health care workers who are employed on a pro re nata, or as-needed, basis, regardless of the number of hours worked. The bill requires the Commissioner to promulgate regulations regarding employee notification and employer recordkeeping requirements. The bill authorizes the Commissioner, in the case of a knowing violation, to subject an employer to a civil penalty not to exceed $150 for the first violation, $300 for the second violation, and $500 for each successive violation. The Commissioner may institute proceedings on behalf of an employee to enforce compliance with the provisions of this bill. Additionally, an aggrieved employee is authorized to bring a civil action against the employer in which he may recover double the amount of any unpaid sick leave and the amount of any actual damages suffered as the result of the employer's violation. The bill has a delayed effective date of January 1, 2025.
STATUS
Introduced
HB212 - MEI Project Approval Commission; board-level gender and diversity requirements.
Vivian E. Watts, Dan I. Helmer, Betsy B. Carr
Last updated 8 months ago
4 Co-Sponsors
MEI Project Approval Commission; board-level gender and diversity requirements. Requires the MEI Project Approval Commission to consider, prior to recommending approval of any major employment and investment (MEI) project, a board diversity disclosure statement submitted by the business seeking incentives. The Commission is required to consider (i) whether such statement specifies the number and percentage of diverse directors who identify as female or as representing a national, racial, ethnic, indigenous, or cultural minority in the country of the business's principal executive offices and (ii) whether the business commits to annually updating and submitting such statement.
STATUS
Vetoed
HB278 - State plan for medical assistance services; fertility preservation treatments, etc.
Dan I. Helmer
Last updated 11 months ago
1 Co-Sponsor
State plan for medical assistance services; fertility preservation treatments; genetic material misuse; penalty. Directs the Board of Medical Assistance Services to amend the state plan for medical assistance services to include a provision for payment of medical assistance for coverage of fertility preservation for individuals diagnosed with cancer who need treatment for that cancer that may cause a substantial risk of sterility or iatrogenic infertility, as defined in the bill, including surgery, radiation, or chemotherapy. The bill also establishes that it is a Class 3 felony for a health care provider to provide assisted conception treatment to a patient and use the health care provider's own gamete without the written consent of the patient.
STATUS
Introduced
HB318 - Firearm industry members; creates standards of responsible conduct, civil liability.
Dan I. Helmer, Nadarius E. Clark, Joshua G. Cole
Last updated 8 months ago
9 Co-Sponsors
Firearm industry members; standards of responsible conduct; civil liability. Creates standards of responsible conduct for firearm industry members and requires such members to establish and implement reasonable controls regarding the manufacture, sale, distribution, use, and marketing of the firearm industry member's firearm-related products, as those terms are defined in the bill. Such reasonable controls include reasonable procedures, safeguards, and business practices that are designed to (i) prevent the sale or distribution of a firearm-related product to a straw purchaser, a firearm trafficker, a person prohibited from possessing a firearm under state or federal law, or a person who the firearm industry member has reasonable cause to believe is at substantial risk of using a firearm-related product to harm themselves or unlawfully harm another or of unlawfully possessing or using a firearm-related product; (ii) prevent the loss of a firearm-related product or theft of a firearm-related product from a firearm industry member; (iii) ensure that the firearm industry member complies with all provisions of state and federal law and does not otherwise promote the unlawful manufacture, sale, possession, marketing, or use of a firearm-related product; and (iv) ensure that the firearm industry member does not engage in an act or practice in violation of the Virginia Consumer Protection Act. The bill also provides that a firearm industry member may not knowingly or recklessly create, maintain, or contribute to a public nuisance, as defined in the bill, through the sale, manufacturing, importing, or marketing of a firearm-related product. The bill creates a civil cause of action for the Attorney General or a local county or city attorney to enforce the provisions of the bill or for any person who has been injured as a result of a firearm industry member's violation to seek an injunction and to recover costs and damages.
STATUS
Vetoed
HB245 - PFAS; facilities that have engaged in manufacture, etc., to produce report on use of chemicals.
David L. Bulova, Dan I. Helmer, Elizabeth B. Bennett-Parker
Last updated 11 months ago
4 Co-Sponsors
Reports relating to PFAS; Department of Environmental Quality; one-time report. Requires all facilities that have engaged since January 1, 2021, in the manufacture of or knowing use in the production process of one or more chemicals listed as PFAS target analytes to produce a one-time report on the use of such chemicals. The report shall be limited to facilities that discharge to (i) a surface water under a Virginia Pollutant Discharge Elimination System permit issued by the Department of Environmental Quality (the Department) or (ii) a publicly owned treatment works under an industrial pretreatment program permit or other written authorization issued by a local permit control authority. The report shall be submitted to the Department and, if such facility discharges to a publicly owned treatment works, also to the local permit control authority no later than October 1, 2024. The bill also requires certain facilities to perform a limited PFAS discharge characterization during the one-year period from October 1, 2024, to September 30, 2025, for each waterway discharge outfall consisting of representative quarterly monitoring using the applicable laboratory test method, as specified in the bill. Such facilities shall report results to the Department and, if the facility discharges to a publicly owned treatment works, also to the local permit control authority, within 30 days after the end of each quarter.
STATUS
Introduced
BIOGRAPHY
INCUMBENT
Representative from Virginia district HD-040
COMMITTEES
Virginia House
BIRTH
--
ABOUT
--
OFFICES HELD
Virginia House from Virginia
NEXT ELECTION
